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Urothelial carcinoma is the most common neoplasm of the
bladder. More than half of all bladder urothelial carcinomas present
as papillary, non-muscle-invasive bladder cancers (NMIBCs), being
either noninvasive (Ta) or lamina propria invasive (T1). The rest are
high-grade and muscularis propria invasive. Because these two
tumor groups behave differently in recurrence, progression, and
cancer-related mortality, different treatment strategies are applied.
NMIBCs are usually treated by transurethral resection (TUR) fol-
lowed by intravesical instillation, whereas high-grade, muscle-
invasive tumors are eligible for cystectomy. Due to the unfavorable
prognosis of muscle-invasive tumors, prognostic indicators that are
able to predict a subset of NMIBC likely to progress are needed to
tailor more aggressive surveillance and management.
2. 1973 World Health Organization classiﬁcation
Among various clinicopathologic parameters, grade and stage
are two most powerful prognosticators. Although TUR specimens
allow for determination of pathologic stage (pT) up to pT2 provided
muscularis propria is adequately sampled,1 tumor grade is an
indispensible element in the pathologic evaluation on all instances.* Corresponding author. Department of Pathology, Taipei Veterans General Hos-
pital, Number 201 Shih-Pai Road, Section 2, Taipei 11217, Taiwan.
E-mail address: ccpan@vghtpe.gov.tw (C.-C. Pan).
q There are 2 CME questions based on this article.
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http://dx.doi.org/10.1016/j.urols.2013.06.006However, the grading of papillary urothelial neoplasms has been a
long-standing issue of debate. Among numerous grading systems,
the 1973 World Health Organization (WHO) system is the most
commonly used.2 A major limitation is its arbitrary deﬁnitions. The
following statement is the sole description of the difference among
WHO Grades 1, 2, and 3 as written in the original WHO 1973 blue
book: “Grade 1 tumors have the least degree of anaplasia
compatible with the diagnosis of malignancy, Grade 3 applies to
tumors with the most severe degrees of cellular anaplasia, and
Grade 2 lies in between”. Although “anaplasia” is further deﬁned as
“increased cellularity, nuclear crowding, disturbances of cellular
polarity, failure of differentiation from the base to the surface,
polymorphism, irregularity in the size of cells, variations of shape
and chromatin pattern of the nuclei, displaced or abnormal mitotic
ﬁgures, and giant cells”, there is no detailed description regarding
how those features are applied to grade the tumor. The vagueness
of the deﬁnition results in most cases falling into the intermediate
category (Grade 2) by default. Also, many pathologists are reluctant
to call a tumor Grade 3 unless the tumor manifests marked
ominous features. For example, our data collected from the surgical
pathologic archive of Taipei Veterans General Hospital from 1991 to
1998 showed that Grade 3 tumors only accounted for around 11% of
all NMIBCs (unpublished data).3. 2004 WHO/ISUP classiﬁcation
In 1998, the International Society of Urological Pathology (ISUP)
proposed a new grading system,3 which was adopted in a large
measure by WHO in 2004.1 The 2004 WHO/ISUP system is a
modiﬁed version of the scheme proposed by Malmström et al.4
Papillary lesions/tumors are classiﬁed as papillary urothelial
neoplasm of low malignant potential (PUNLMP), low-grade papil-
lary urothelial carcinoma or high-grade papillary urothelial carci-
noma. The new2004WHO/ISUP scheme, with the strength of clear-
cut criteria for each entity and the aim of eliminating subjective and
arbitrary interpretation, greatly improves the ambiguous language
that marked the 1973 WHO system. Fig. 1 shows the algorithm of
diagnosing papillary NMIBC. On the basis of the 2004 WHO/ISUPan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Flow chart of the differential diagnosis of papillary urothelial lesions/tumors.
Table 1
Reported risk of recurrence, progression, and cancer-speciﬁc mortality by papillary
urothelial neoplasm.
Papilloma PUNLMP Low-grade
carcinoma
High-grade
carcinoma
Recurrence 0e31 17e52 34e77 34e73
Progression 0 0e7 4e18 8e35
Cancer-speciﬁc
mortality
0 0e1a 0e5 4e22
Data are presented as %.
PUNLMP ¼ papillary urothelial neoplasm of low malignant potential.
a Only one patient with PUNLMP who died of progressive bladder cancer was
reported.
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noma, and high-grade papillary urothelial carcinoma accounted for
14%, 47%, and 39%, respectively, in our series of 1515 NIMBCs.5
Following are brief descriptions regarding the entities deﬁned in
the 2004 WHO/ISUP system.
3.1. Papillary urothelial hyperplasia
Papillary urothelial hyperplasia lacks true branching papillary
fronds, but consists of undulating urothelium arranged into
mucosal narrow papillary folds of varying heights. The cytologic
ﬁndings in papillary hyperplasia are similar to those in normal
urothelium. Papillary hyperplasia is a likely precursor lesion to low-
grade papillary urothelial neoplasms. It is reasonable to suggest
that patients should be followed-up, even though de novo papillary
hyperplasia will not progress to urothelial neoplasia in most in-
stances. If papillary hyperplasia is found in an individual with a
prior history of urothelial neoplasm, it indicates early recurrence
that warrants continued close follow-up.
3.2. Urothelial papilloma
Urothelial papillomas consists of papillary fronds lined by
normal appearing urothelium. Although the criteria for diagnosis
do not include the absolute number of cell layers, the urothelium
should not be obviously thicker than normal urothelium, otherwise
the lesion had better be classiﬁed as PUNLMP. Papillomas are rare
and typically, but not exclusively, occur in younger patients.
3.3. PUNLMP
PUNLMP is characterized by papillae with predominantly
orderly architecture and minimal cytologic atypia. PUNLMPs at low
magniﬁcation differ from papillomas by having thicker urothelium.
A properly diagnosed PUNLMP never invades andmetastasizes (see
discussion below).
3.4. Low-grade papillary urothelial carcinoma
Low-grade papillary urothelial carcinoma shows an orderly
appearance but easily recognizable variations in architecture and
cytologic features (polarity, nuclear size, shape, and chromatin
texture). The majority of low-grade carcinoma are noninvasive (Ta).
In the uncommon cases that invade the lamina propria (T1),the invasion is mostly focal.6 A diagnosis such as low-grade uro-
thelial carcinoma with a stage higher than T1 should be met with
criticism.3.5. High-grade papillary urothelial carcinoma
High-grade papillary urothelial carcinoma shows a predominant
pattern of disorder and/or marked cytologic atypia. High-grade
carcinomas frequently invade and metastasize. Carcinomas with
extensive lamina propria invasion or stage higher than T1 are
virtually all high-grade. High-grade carcinomas have a higher as-
sociation with larger tumor size, multiplicity, and carcinoma in
situ.74. Translation of 1973 WHO to 2004 WHO/ISUP system
A potential confusion about the two grading systems concerns
the relationship between the old and new classiﬁcation. There is
no one-to-one translation between the two systems. The deﬁnition
of papilloma in the 1973 WHO system is the same as that in the
2004 WHO/ISUP system. At the other end of the grading extreme,
all 1973 WHO Grade 3 tumors are assigned to the high-grade
carcinoma category in the 2004 WHO/ISUP system. By contrast,
there is no direct translation to the 2004 WHO/ISUP classiﬁcation
for 1973 WHO Grades 1 and 2 carcinomas.8 This change of deﬁ-
nition may entail some difﬁculties in applying a nomogram or
prognostic table that employ the 1973 WHO system.9 Also, previ-
ous articles where the 1973 WHO terminologies were directly
translated into the 2004 WHO/ISUP ones should be interpreted
with caution.5. Prognostic signiﬁcance
There are marked trends of higher risks for recurrence, pro-
gression, and cancer-speciﬁc mortality with higher grades.5,10e22
Table 1 lists the ranges of risks reported in previous studies. The
considerable variability in the reported recurrence and progression
rates may be related to the duration of follow-up, different inclu-
sion criteria for diagnosing recurrence (histologically proven cases
vs. cases diagnosed solely based on cystoscopic/cytologic ﬁndings),
and progression (any advance of stage, advance to muscle-invasive
disease, progression to higher grade/carcinoma in situ). Our series
showed that PUNLMP had a recurrence rate of 17.9%, a progression
rate of 1.9%, and a 0% cancer mortality rate, where recurrence was
deﬁned as the reappearance of histopathologically conﬁrmed uro-
thelial neoplasm in the bladder and progressionwas deﬁned as any
advance in stage (from pTa to pT1e4, from pT1 to pT2e4), diagnosis
of metastasis, or death caused by tumor. The recurrence rate, pro-
gression rate, and cancer mortality rate of low-grade carcinomas
were 35.0%, 6.5%, and 2.0%, respectively. By contrast, 34.0% of high-
Table 2
Bootstrapped (200) Kaplan-Meier survival estimate for recurrence-free survival, progression-free survival, and cancer-speciﬁc survival for patients receiving intravesical
instillation (1,102 cases).
Recurrence-free survival 95% CI Progression-free survival 95% CI cancer-speciﬁc survival 95% CI
1 yr 3 yr 5 yr 8 yr 1 yr 3 yr 5 yr 8 yr 1 yr 3 yr 5 yr 8 yr
PUNLMP 93.2 80.2 83.6 78.9 99.0 98.0 96.9 96.9 100 100 100 100
92.8e93.5 79.7e80.7 83.2e84.0 78.5e79.4 98.9e99.2 97.8e98.2 96.6e97.2 96.7e97.2 d d d d
LPUC Ta 85.9 70.1 66.3 61.8 98.6 95.7 93.6 91.1 99.5 98.4 98.4 97.6
85.7e86.1 69.9e70.4 66.0e66.6 61.5e62.1 98.5e98.6 95.6e95.8 93.5e93.8 90.9e91.3 99.5e99.6 98.4e98.5 98.4e98.6 97.5e97.7
LPUC T1 83.3 67.3 65.4 59.1 96.9 93.7 92.1 87.9 99.0 96.5 93.6 91.4
82.7e83.8 66.5e68.0 64.6e66.1 58.3e59.8 96.6e97.1 93.3e94.0 91.7e92.5 87.4e88.5 98.7e99.0 96.2e96.8 93.2e94.0 90.9e91.8
HPUC Ta 85.4 65.2 57.7 54.4 91.0 82.6 78.8 73.7 94.4 90.9 88.2 86.8
85.0e85.7 64.7e65.8 57.2e58.3 53.9e55.0 90.8e91.3 82.2e83.0 78.3e79.1 73.2e74.2 94.1e94.6 90.5e91.2 87.9e88.6 86.4e87.1
HPUC T1 85.1 63.9 55.1 49.8 85.6 70.8 64.4 61.3 87.1 74.3 70.4 65.7
84.8e85.4 63.5e64.3 54.8e55.5 49.3e50.2 85.3e85.8 70.5e71.2 64.0e64.7 60.9e61.7 86.9e87.3 74.0e74.6 70.1e70.7 65.4e66.1
Data are presented as %.
CI¼ conﬁdence interval; HPUC¼ high-grade papillary urothelial carcinoma; LPUC¼ low-grade papillary urothelial carcinoma; PUNLMP¼ papillary urothelial neoplasm of low
malignant potential.
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cancer death.
Taking both grade and stage into consideration, we are able to
identify signiﬁcant differences and trends for higher progression
and cancer-speciﬁc mortality cumulative incidence in the following
order: PUNLMP, low-grade carcinoma; Ta, high-grade carcinoma;
and T1, high-grade carcinoma (Fig. 2).5,7 Tables 2 and 3 show our
updated 1-year, 3-year, 5-year, and 8-year bootstrapped
recurrence-free, progression-free, and cancer-speciﬁc survivals for
patients with NMIBC treated by TUR with or without adjuvant
intravesical instillation.
Compared with stage, tumor grade was more predictive of
progression and cancer-speciﬁc mortality for patients with NMIBC.
The biologic behavior of urothelial tumors is ﬁrst determined by
grade, then by stage within the same grade. It should be noted that
a T1 low-grade papillary urothelial carcinoma has better prognosis
than a Ta high-grade papillary urothelial carcinoma. This seem-
ingly paradoxical ﬁnding is related to the nature of urothelial tu-
mors and also to the surgical modality. The TUR procedure
removes visible tumor and a part of the bladder tissue rather than
the entire bladder; therefore, whether residual or multifocal tu-
mors remain largely determines the subsequent course of the
disease. It is plausible that T1 low-grade papillary urothelial car-
cinomas are mostly eradicable by TUR, and even if some recur their
indolent nature and limited ability to invade ensure that the stage
remains unchanged. Contrary to low-grade papillary urothelial
carcinomas, high-grade papillary urothelial carcinomas, althoughTable 3
Bootstrapped (200) Kaplan-Meier survival estimate for recurrence-free survival, prog
intravesical instillation (661 cases).
Recurrence-free survival 95% CI Progression-
1 yr 3 yr 5 yr 8 yr 1 yr 3 yr
PUNLMP 96.2 94.1 91.8 88.2 100 100
95.9e96.5 93.8e94.4 91.3e92.2 87.6e88.7 d d
LPUC Ta 87.1 74.9 71.4 67.0 97.3 93.5
86.8e87.5 74.4e75.4 71.0e71.9 66.5e67.6 97.1e97.5 93.2e93
LPUC T1 83.1 75.4 69.3 69.2 93.1 88.8
82.1e84.1 74.2e76.6 68.0e70.6 67.8e70.5 92.5e93.8 88.2e89
HPUC Ta 90.9 77.3 65.8 65.4 89.1 73.5
90.4e91.6 76.3e78.2 64.7e66.8 64.3e66.7 88.5e89.6 72.6e74
HPUC T1 84.2 71.3 69.1 69.1 71.6 50.8
83.7e84.7 70.7e72.0 68.6e69.6 68.6e69.6 71.1e72.2 50.1e51
Data are presented as %.
CI¼ conﬁdence interval; HPUC¼ high-grade papillary urothelial carcinoma; LPUC¼ low-g
malignant potential.noninvasive at initial presentation sometimes, have a remarkable
association with multifocality and carcinoma in situ; thus, they
possess a propensity for progression that leads to cancer-speciﬁc
mortality.6
6. PUNLMP controversies
The most controversial aspect of the WHO/ISUP grading system
is the category of PUNLMP. Accumulated data have shown a deﬁ-
nite, yet lower, incidence of recurrence in PUNLMP in comparison
with low-grade papillary urothelial carcinoma. The progression
rate is negligible, with most series reporting a null ﬁgure. All pre-
vious studies also noted a 0% mortality rate with the exception of
Oosterhuis et al18 who reported the death of one patient (out of
116) as a consequence of progression and dissemination of an
invasive bladder carcinoma. Given the indolent nature of PUNLMP,
it is reasonable to discourage the use of the term “carcinoma” in
patients with PUNLMP because the expected clinical behavior is
better reﬂected by the terminology “low malignant potential”.15
Urologists often express their concerns about PUNLMP as to
whether the patients are justiﬁed to be exempt from follow-up
cystoscopic examination. Because even a benign papilloma still
bears a low likelihood to recur, it is judicious to follow-up all pa-
tients with every sort of papillary neoplasm. Some investigators
have proposed that patients with PUNLMP may be submitted to
fewer cystoscopies if the number of lesions is few and no re-
currences are seen during initial surveillance period. The beneﬁt ofression-free survival, and cancer-speciﬁc survival for patients who did not receive
free survival 95% CI Cancer-speciﬁc survival 95% CI
5 yr 8 yr 1 yr 3 yr 5 yr 8 yr
100 100 100 100 100 100
d d d d d d
92.0 88.1 98.9 97.2 97.1 96.0
.8 91.7e92.3 87.7e88.5 98.8e99.0 97.1e97.4 96.9e97.3 95.6e96.1
88.3 87.9 96.6 92.7 92.4 92.4
.4 87.7e88.9 87.2e88.6 96.1e97.0 92.0e93.4 91.7e93.1 91.7e93.1
67.5 64.4 89.5 78.0 71.8 68.0
.4 66.5e68.6 63.3e65.4 88.9e90.1 77.2e78.7 70.7e72.8 66.9e69.1
46.2 41.2 73.2 53.0 48.6 43.7
.4 45.5e46.8 40.6e41.8 72.7e73.8 52.4e53.6 48.0e49.3 43.0e44.4
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Fig. 2. Cumulative incidence plots of (A) progression, (B) cancer-speciﬁc mortality, and (C) recurrence for patients with non-muscle-invasive bladder tumors of different grades and
stages. HPUC ¼ high-grade papillary urothelial carcinoma; LPUC ¼ low-grade papillary urothelial carcinoma; PUNLMP ¼ papillary urothelial neoplasm of low malignant potential.
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vestigations to assess.
7. Conclusion
The 2004 WHO/ISUP system has advantages, but also limita-
tions. Even with a clearer deﬁnition than the 1973 WHO system,
interobserver reproducibility still leaves something to be desired.23
In real practice, a certain level of diagnostic variation undoubtedly
exists. Further consensus meetings and educational conferences
and programs should improve the situation. The grading system
requires reﬁnement in terms of tumor heterogeneity. Utility of
biological and molecular markers may enhance the efﬁcacy of the
grading, yet so far there have not been markers sufﬁcient to replace
the histological grading.
Currently, the 2004 WHO/ISUP scheme has been adopted in the
National Comprehensive Cancer Network guidelines for treating
bladder cancers (http://www.nccn.org). We anticipate wider
acceptance and proper use of the classiﬁcation system among pa-
thologists and urologists so that histological grading can be a truly
valuable indicator that contributes to the design of therapeutic and
monitoring strategies for patients with urothelial cancer.Conﬂicts of interest statement
The authors declare that they have no ﬁnancial or non-ﬁnancial
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